Healthcare -
Medical - Instruments & Supplies - NASDAQ - IL
$ 0.1695
-13.8 %
$ 4.34 M
Market Cap
None
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart GCTK
FINANCIALS
Balance Sheet
GlucoTrack, Inc.
| Current Assets | 5.77 M |
| Cash & Short-Term Investments | 5.62 M |
| Receivables | 0 |
| Other Current Assets | 151 K |
| Non-Current Assets | 164 K |
| Long-Term Investments | 0 |
| PP&E | 154 K |
| Other Non-Current Assets | 10 K |
| Current Liabilities | 1.28 M |
| Accounts Payable | 992 K |
| Short-Term Debt | 5 K |
| Other Current Liabilities | 278 K |
| Non-Current Liabilities | 17.7 M |
| Long-Term Debt | 203 K |
| Other Non-Current Liabilities | 17.5 M |
EFFICIENCY
Earnings Waterfall
GlucoTrack, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 0 |
| Operating Income | 0 |
| Other Expenses | 22.6 M |
| Net Income | -22.6 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
GlucoTrack, Inc.
| Net Income | -22.6 M |
| Depreciation & Amortization | 36 K |
| Capital Expenditures | -104 K |
| Stock-Based Compensation | 173 K |
| Change in Working Capital | 67 K |
| Others | 9.64 M |
| Free Cash Flow | -12.6 M |
Wall Street Analysts Price Targets
GlucoTrack, Inc.
GCTK has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
GCTK does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
GlucoTrack, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
25.1 M USD 6
9-12 MONTHS
7. News
Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas
RUTHERFORD, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the FORGETDIABETES bionic pancreas initiative that will develop a long-term, automated insulin delivery system that will enable optimal glucose control without patient intervention.
globenewswire.com
- 1 month ago
Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor
Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study Data Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study Data
globenewswire.com
- 1 month ago
Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights
Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption (IDE) approval for continuous blood glucose monitoring (CBGM) technology from FDA expected in Q4 2025 Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2024. “2024 was transformative for Glucotrack as we advanced the development of our CBGM technology and successfully transitioned from a preclinical to a clinical stage company.
globenewswire.com
- 1 month ago
Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes
Safety and performance data from direct blood glucose measurement technology to be featured at international diabetes technology conference Safety and performance data from direct blood glucose measurement technology to be featured at international diabetes technology conference
globenewswire.com
- 2 months ago
Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member
Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology
globenewswire.com
- 2 months ago
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a “best efforts” public offering of approximately 2.6 million shares of common stock. The offering price of each share of common stock is $1.15, The gross proceeds of the public offering are expected to be approximately $3.0 million before deducting agent placement fees and offering expenses. The closing of the public offering is expected to occur on or about February 5, 2025, subject to the satisfaction of customary closing conditions.
globenewswire.com
- 3 months ago
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
The study met its primary endpoint with no procedure or device related serious adverse events reported The study met its primary endpoint with no procedure or device related serious adverse events reported
globenewswire.com
- 3 months ago
Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer
Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes
globenewswire.com
- 3 months ago
Glucotrack Announces ISO 13485:2016 Certification
ISO Certification highlights commitment to quality for continuous blood glucose monitor ISO Certification highlights commitment to quality for continuous blood glucose monitor
globenewswire.com
- 3 months ago
Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs
New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes
globenewswire.com
- 4 months ago
Glucotrack to Present at TechBio Showcase™ 2025
Presentation to feature an update on the Company's novel continuous blood glucose monitor for patients with diabetes Presentation to feature an update on the Company's novel continuous blood glucose monitor for patients with diabetes
globenewswire.com
- 4 months ago
GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR
Feasibility study underway for the Company's novel continuous blood glucose monitor in patients with diabetes, with data expected within 6-8 weeks
globenewswire.com
- 5 months ago
8. Profile
Summary
GlucoTrack, Inc. GCTK
COUNTRY
IL
INDUSTRY
Medical - Instruments & Supplies
MARKET CAP
$ 4.34 M
Dividend Yield
0.00%
Description
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
Contact
8 Ariel Sharon Street, Or Yehuda, 7760049
https://www.glucotrack.com
IPO
Date
April 25, 2013
Employees
11
Officers
Mr. Avner Gal MBA, MSc.EE
Co-Founder, Chairman Emeritus, Consultant and Member of Scientific & Clinical Advisory Board
Mr. David Malka BA
Co-Founder
Mr. Vincent Wong
Vice President of Operations
Ms. Drinda Benjamin
Vice President of Marketing
Mr. Paul V. Goode Ph.D.
Chief Executive Officer, President & Director
Mr. Peter C. Wulff
Chief Financial Officer, Treasurer & Secretary
Mr. Mark Tapsak Ph.D.
Chief Scientific Officer